8 February 2022
Oncode Institute and ArgoBio launch Laigo Bio
ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.
3 February 2022
Patiënten en onderzoekers versterken elkaar tijdens Wereldkankerdag
[English tekst & video included] Ieder jaar wordt op 4 februari wereldwijd stilgestaan bij de impact van kanker tijdens Wereldkankerdag. Fundamentele kankeronderzoekers en kankerpatiënten leven in verschillende werelden die elkaar niet vaak ontmoeten. In deze video leggen Inge Reus en Niels Heine, twee deelnemers van Oncode’s Patiënt Perspectief Programma, samen met Oncode Investigator Peter ten Dijke van het Leids Universitair Medisch Centrum uit welke waarde de samenwerking tussen (ex-)patiënten en onderzoekers heeft.
1 February 2022
Hans Clevers starts a new challenge at Roche
As of March 18, Hans Clevers, Oncode Investigator and one of Oncode’s founding scientists, will head Roche Pharmaceutical Research and Early Development (pRED) and become a member of the Corporate Executive Committee at Roche in Basel, Switzerland. In this new role, he will lead research into the development of drugs for a wide variety of diseases. Hans will stay closely connected to the Oncode research community.
31 January 2022
Optimized colorectal cancer (CRC) catalogue available for all researchers
The Colorectal Cancer (CRC) catalogue - a platform on which you can find all the available biomaterials and omics data within the colorectal cancer, small intestinal cancer, and anal cancer clinical studies in the Netherlands ̶ has now been updated and expanded. More than 40 studies are now included, which together make for more than 30,000 biological samples of CRC patients.
25 January 2022
Onderzoekers ontmoeten patiënten: Highlights van het patiënt perspectief event
(English version included) Onlangs organiseerde Oncode een event binnen het Patiënt Perspectief Programma, waar (ex)patiënten en onderzoekers elkaar konden spreken en ervaringen uitwisselen. Lees hier de highlights!
17 January 2022
Oncode collaboration: mobilizing innate leukocytes to attack tumors
In 2021, Oncode Institute organized brainstorm sessions to come up with ideas for cross-disciplinary synergies between Oncode researchers to tackle difficult challenges in cancer research. A group of Oncode Investigators from different institutes* came up with an exciting new idea requiring their collaboration to become successful. This launched a new Oncode Accelerator Project: mobilizing innate leukocytes to attack tumors
1 December 2021
Oncode spin-off Immagene announces seed investment round to progress novel Immuno-Oncology therapeutics
Immagene B.V., a spin-off of the Netherlands Cancer Institute (NKI) and Oncode Institute, today announces it has raised a seed financing round to advance its next-generation precision Immuno-Oncology (IO) therapeutics. BOM Brabant Ventures joined as a new investor with additional support from existing investors Swanbridge Capital and Oncode Oncology Bridge Fund.
30 November 2021
More than science: highlights from the Oncode CGC Annual Conference
Did you attend Oncode’s Annual Conference at the Royal Tropical Institute at the beginning of November? If not, you’ve been missing out. Was it the wide variety of topics presented by a great mix of experts who delivered their knowledge with passion and insight, both in person and online? Was it the energy and joy that came from being able to get together face to face, right before a new lockdown? In any case, make sure to check out the highlights!
29 November 2021
CPoC grants awarded: New treatments for vulvar cancer & malignant mesothelioma
Oncode Institute aims to link fundamental and clinical research to enable efficient translation of promising findings into novel diagnostic methods and clinical treatment strategies. Oncode created the clinical Proof-of-Concept (cPoC) fund to support the clinical translation of Oncode’s fundamental research. Oncode Institute is pleased to announce that the 14th and 15th grants within the Clinical Proof of Concept programme have been awarded: less radical treatments for vulvar cancer and new drug combinations for malignant mesothelioma.
25 November 2021
Oncode shows it can be done in a different way: an interview with Hans Clevers
How can we as a society benefit even more from the knowledge that is being developed at our Dutch universities? How do you transfer this knowledge into innovations that boost our economy and offer solutions to our major societal challenges? These are some of the questions at the core of Oncode Institute. Oncode Investigator Hans Clevers, co-founder of Oncode Institute and professor Molecular Genetics at Utrecht University and UMC Utrecht answers them in this interview conducted by Teachleap.nl in collaboration with Innovation Origins.
25 November 2021
Oncode Investigator Sylvie Noordermeer: ‘Setting up your own research group is both exciting ánd terrifying’
Creating your own research group is exciting, but what are some of the typical challenges that can emerge? Oncode Investigator Sylvie Noordermeer (LUMC) discusses her experiences as founder of the Noordermeer research group, whilst also reflecting on the contribution that Oncode’s Mentoring Programme can make in solving dilemmas.
17 November 2021
Oncode-PACT proposal submitted to Growth Fund
Oncode Institute is proud to announce that the Ministry of Economic Affairs and Climate Policy formally decided to submit the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) proposal to the Growth Fund (Groeifonds) Commission on November 1st, 2021.
Scroll for more